Lifespan Vision Ventures

Established in 2022, Lifespan Vision Ventures is a venture capital firm headquartered in Norwalk, Connecticut. The company focuses on investing in therapeutics businesses that specialize in longevity and aging reversal.

Harry Robb

Analyst

10 past transactions

EpiBone

Convertible Note in 2024
EpiBone is a biotechnology company specializing in regenerative medicine for bone repair. It uses patient-specific stem cells and 3D fabrication to create living, anatomically precise bone grafts. The company's lead product has completed Phase I/IIa clinical trials, with additional products focusing on cartilage repair under development.

LIfT BioSciences

Series A in 2024
Founded in London in 2016, LIfT BioSciences develops a proprietary platform for allogeneic innate immuno-cell therapy. Its Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) enables scalable production of Immunomodulatory Alpha Neutrophils (IMAN®s) from induced pluripotent stem cells (iPSCs), offering potential mono or combo therapies.

Remedium Bio

Seed Round in 2024
Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for a variety of debilitating conditions. The company employs a unique approach that combines established technologies in innovative ways to address well-defined disease mechanisms. By modularly applying these proven technologies, Remedium Bio focuses on creating localized and targeted therapies centered on clinically validated molecules and pathways. Its pipeline includes leading gene therapy candidates in multiple fields, such as rheumatology, endocrinology, and neurology, aimed at providing effective treatments for a range of immune, age-related, and metabolic disorders.

Immunis

Venture Round in 2024
Immunis is a private biotechnology company focused on addressing age and disease-related immune decline through innovative stem cell-derived therapies. The company specializes in utilizing human stem cells to create specific populations of cells that secrete therapeutic factors. This approach aims to enable healthcare professionals to enhance immune system development, modulation, and overall health in patients. By harnessing the potential of stem cell technology, Immunis seeks to offer novel treatment options that can improve immune function and combat the effects of aging and various diseases.

Senisca

Venture Round in 2024
Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Bolden Therapeutics

Venture Round in 2024
Bolden Therapeutics is a biotechnology company focused on developing first-in-class therapeutics for treating central nervous system diseases. Its primary approach involves promoting the birth of new neurons in the adult brain to address conditions like Alzheimer's disease and ischemic stroke.

NaNotics

Venture Round in 2023
NaNotics develops a nanomedical platform designed for treating autoimmune disorders and solid tumor malignancies. Its platform uses nanoparticles injected like a drug to rapidly and safely target and deplete disease-causing molecules in the bloodstream, providing physicians with a new and safe treatment modality.

Matter Bio

Venture Round in 2023
Matter Bio is a biotechnology company dedicated to preserving genomic integrity. It offers research services aimed at enhancing longevity by safeguarding and utilising DNA information. The company's primary focus is assembling an elite team of scientists and executives to combat genetic mutations and extend patient lifespan through innovative approaches to reverse such mutations.

Rejuvenation Technologies

Venture Round in 2023
Founded in 2016, Rejuvenation Technologies is a biotechnology company based in Mountain View, California. It specializes in developing nucleoside-modified TERT mRNA to safely extend telomeres for human health extension.

Integrated Biosciences

Pre Seed Round in 2022
Integrated Biosciences focuses on developing innovative therapeutics aimed at combating age-related diseases. Founded on research from prestigious institutions such as Harvard, MIT, and UCSB, the company has made significant strides in the field, including the first AI-driven discovery of anti-aging drug candidates and the introduction of a novel structural class of antibiotics in six decades. By leveraging synthetic biology and machine learning, Integrated Biosciences seeks to control cellular stress responses, facilitating advancements in cellular rejuvenation and empowering medical professionals with next-generation treatment options.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.